Zobrazeno 1 - 10
of 102
pro vyhledávání: '"Naoya Saito"'
Publikováno v:
PLoS ONE, Vol 19, Iss 5, p e0303614 (2024)
HER2 expression in breast cancer is evaluated to select patients for anti-HER2 therapy. With the advent of newly approved HER2-targeted drugs for low HER2 expression breast cancer, more solid evidence on the whole spectrum of HER2 expression is neede
Externí odkaz:
https://doaj.org/article/eda75b4f5b5049ff8dfca425e14eed72
Autor:
Taichi Morita, Masafumi Edamoto, Satoshi Miura, Atsushi Sunahara, Naoya Saito, Yutaro Itadani, Tomihiko Kojima, Yoshitaka Mori, Tomoyuki Johzaki, Yoshihiro Kajimura, Shinsuke Fujioka, Akifumi Yogo, Hiroaki Nishimura, Hideki Nakashima, Naoji Yamamoto
Publikováno v:
Scientific Reports, Vol 7, Iss 1, Pp 1-7 (2017)
Abstract We report an experimental demonstration of controlling plasma flow direction with a magnetic nozzle consisting of multiple coils. Four coils are controlled separately to form an asymmetric magnetic field to change the direction of laser-prod
Externí odkaz:
https://doaj.org/article/95448502f1fe48988f19c339536dac6c
Autor:
Takumi Kawabe, Daniel D. VonHoff, Donald W. Kufe, Jonathan M. Friedman, Takuji Sato, Keiichi Sakakibara, Naoya Saito
Supplementary Figure 8: MLN4924 attenuates tumor growth inhibition by CBS9106 in human xenograft model. (A) SCID mice bearing HCT116 tumor xenografts are treated with vehicle (5% GA, p.o. + 10% HBC, s.c.), CBS9106 (250 mg/kg p.o. once per week), MLN4
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8e9e48038b36b2f6bd252c9bd54185c9
https://doi.org/10.1158/1535-7163.22499652.v1
https://doi.org/10.1158/1535-7163.22499652.v1
Autor:
Takumi Kawabe, Daniel D. Von Hoff, Donald W. Kufe, Machiyo Ishigaki, Chikako Suda, Satoshi Yamazaki, Naoya Saito, Sayaka Yamamoto, Naoki Mine
PDF file -62K
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4f2167e4f0f051fc6ee3d85f20738a23
https://doi.org/10.1158/1535-7163.22496268.v1
https://doi.org/10.1158/1535-7163.22496268.v1
Autor:
Takumi Kawabe, Daniel D. Von Hoff, Donald W. Kufe, Machiyo Ishigaki, Chikako Suda, Satoshi Yamazaki, Naoya Saito, Sayaka Yamamoto, Naoki Mine
CBP501 is an anticancer drug currently in randomized phase II clinical trials for patients with non–small cell lung cancer and malignant pleural mesothelioma. CBP501 was originally described as a unique G2 checkpoint-directed agent that binds to 14
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a573389697e666d78dceabb2f7cd7e13
https://doi.org/10.1158/1535-7163.c.6535212.v1
https://doi.org/10.1158/1535-7163.c.6535212.v1
Autor:
Takumi Kawabe, Daniel D. VonHoff, Donald W. Kufe, Jonathan M. Friedman, Takuji Sato, Keiichi Sakakibara, Naoya Saito
Supplementary Figure 2: MLN4924 (50 nM) increases subG1 and DNA content. HCT116 cells are treated with increasing concentrations of MLN4924 (0, 1, 10, or 50 nM) for 72 hours. The population is measured by flow cytometry after staining with propidium
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0edb3814a383b57738d98b140c3658f0
https://doi.org/10.1158/1535-7163.22499670
https://doi.org/10.1158/1535-7163.22499670
Autor:
Takumi Kawabe, Daniel D. VonHoff, Donald W. Kufe, Jonathan M. Friedman, Takuji Sato, Keiichi Sakakibara, Naoya Saito
Supplementary Figure 1: CBS9106 reduces CRM1 protein levels through neddylation -mediated degradation in MM.1S cells. (A) MM.1S cells are treated with CBS9106 (50 nM) and/or MLN4924 (100 nM) for indicated period (0-8 hours). (B) Cells are treated wit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4d1dac22335be4ababc4fd71cffe4c02
https://doi.org/10.1158/1535-7163.22499673
https://doi.org/10.1158/1535-7163.22499673
Autor:
Takumi Kawabe, Daniel D. VonHoff, Donald W. Kufe, Jonathan M. Friedman, Takuji Sato, Keiichi Sakakibara, Naoya Saito
Supplementary Figure 6: Inhibitors of autophagy do not interfere with the efficacy of low dose MLN4924. HCT116 cells are treated with CBS9106 (100 nM), MLN4924 (50 nM or 1 microM) or 3-MA (5 mM) alone or in combination for 24 hours. Protein levels of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::45a8e928ca7b4deccfebb2571b0bc4b5
https://doi.org/10.1158/1535-7163.22499658
https://doi.org/10.1158/1535-7163.22499658
Autor:
Takumi Kawabe, Daniel D. VonHoff, Donald W. Kufe, Jonathan M. Friedman, Takuji Sato, Keiichi Sakakibara, Naoya Saito
Supplementary Figure 7: Schematic representation that summarizes the proposed mechanism of action of CBS9106.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ca21ce9db7933b12a8f9bb209b073fb6
https://doi.org/10.1158/1535-7163.22499655
https://doi.org/10.1158/1535-7163.22499655
Autor:
Takumi Kawabe, Daniel D. VonHoff, Donald W. Kufe, Jonathan M. Friedman, Takuji Sato, Keiichi Sakakibara, Naoya Saito
Supplementary Figure 3: The cell growth inhibition and apoptosis by CBS9106 is suppressed by MLN4924 in MM.1S cells. (A) MM.1S cells are treated with the indicated concentration of CBS9106 and/or MLN4924 for 72 hours (n = 6). Cell viability is determ
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7511f730693f2044f6d4f116f8115835
https://doi.org/10.1158/1535-7163.22499667
https://doi.org/10.1158/1535-7163.22499667